NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Autologous chondrocyte implantation with chondrosphere for treating articular cartilage defects [ID851]

Final matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Company	General
Co.don AG (chondrosphere)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Action on Pain	Board of Community Health Councils in
Arthritis Action	Wales
Arthritis & Musculoskeletal Alliance	British National Formulary
Arthritis Care	Care Quality Commission
Disability Rights UK	Department of Health, Social Services
 Leonard Cheshire Disability 	and Public Safety for Northern Ireland
Muslim Council of Britain	Healthcare Improvement Scotland
Pain Concern	Medicines and Healthcare products
Pain Relief Foundation	Regulatory Agency
Pain UK	National Association of Primary Care
South Asian Health Foundation	National Pharmacy Association
Specialised Healthcare Alliance	NHS Alliance
	NHS Commercial Medicines Unit
Professional groups	NHS Confederation
Association of Anaesthetists	Scottish Medicines Consortium
Association of Surgeons of Great Pritain and Iraland	Welsh Health Specialised Services Committee
Britain and Ireland	Committee
 British Association for Surgery of the Knee 	Comparator companies
 British Association of Day Surgery 	ACI (Robert Jones & Agnes Hunt
 British Association of Day Surgery British Geriatrics Society 	Orthopaedic & District Hospital NHS
British Institute of Musculoskeletal	Trust)
Medicine	Vericel (Matrix applied characterised
British Institute of Radiology	autologous cultured chondrocyte
British Orthopaedic Association	implant – MACI)
British Pain Society	
British Society for Gene and Cell	Relevant research groups
Therapy	Arthritis Research UK
British Society for Rheumatology	Bone Research Society
British Society of Rehabilitation	Chronic Pain Policy Coalition
Medicine	Cochrane Musculoskeletal Group

National Institute for Health and Care Excellence

Final matrix for the technology appraisal of autologous chondrocyte implantation with chondrosphere for treating articular cartilage defects [ID851]

Issue date: June 2017 Page 1 of 3

Consultees		Commentators (no right to submit or appeal)
• • • • • • • • • • • • • • • • • • •	British Trauma Society Chartered Society of Physiotherapy Physiotherapy Pain Association Primary Care Rheumatology Society Rheumatoid Arthritis Surgical Society Royal College of Anaesthetists Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal College of Surgeons Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association	 MRC Clinical Trials Unit National Institute for Health Research UK Stem Cell Foundation Associated Public Health groups Public Health England Public Health Wales
•	Department of Health	
•	NHS England	
•	NHS Bexley CCG	
•	NHS Central Manchester CCG	
•	Welsh Government	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

National Institute for Health and Care Excellence Final matrix for the technology appraisal of autologous chondrocyte implantation with chondrosphere for treating articular cartilage defects [ID851]

Issue date: June 2017 Page 2 of 3

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland;; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-company commentators are invited to nominate clinical or patient experts.

National Institute for Health and Care Excellence Final matrix for the technology appraisal of autologous chondrocyte implantation with chondrosphere for treating articular cartilage defects [ID851]

Issue date: June 2017 Page 3 of 3

-

¹ Non company consultees are invited to submit statements relevant to the group they are representing.